225 related articles for article (PubMed ID: 16338277)
1. Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists.
Babaoglu MO; Bayar B; Aynacioglu AS; Kerb R; Abali H; Celik I; Bozkurt A
Clin Pharmacol Ther; 2005 Dec; 78(6):619-26. PubMed ID: 16338277
[TBL] [Abstract][Full Text] [Related]
2. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
Slabý J; Trnený M; Procházka B; Klener P
Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
[TBL] [Abstract][Full Text] [Related]
4. Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
Massidda B; Ionta MT
J Chemother; 1996 Jun; 8(3):237-42. PubMed ID: 8808724
[TBL] [Abstract][Full Text] [Related]
5. Association of ABCB1 polymorphisms with the antiemetic efficacy of granisetron plus dexamethasone in breast cancer patients.
Tsuji D; Kim YI; Nakamichi H; Daimon T; Suwa K; Iwabe Y; Hayashi H; Inoue K; Yoshida M; Itoh K
Drug Metab Pharmacokinet; 2013; 28(4):299-304. PubMed ID: 23358260
[TBL] [Abstract][Full Text] [Related]
6. [Clinical evaluation of antiemetic effects of 5-hydroxytryptamine receptor type 3 (5HT3 receptor) antagonists based on changes in eating condition in cancer patients receiving chemotherapy].
Okuyama K; Yoshimoto K; Iwase O; Ozeki T; Yamada Y
Yakugaku Zasshi; 2008 Apr; 128(4):649-55. PubMed ID: 18379183
[TBL] [Abstract][Full Text] [Related]
7. Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
Aksoylar S; Akman SA; Ozgenç F; Kansoy S
Pediatr Hematol Oncol; 2001 Sep; 18(6):397-406. PubMed ID: 11554235
[TBL] [Abstract][Full Text] [Related]
8. Ondansetron and tropisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
Stiakaki E; Savvas S; Lydaki E; Bolonaki I; Kouvidi E; Dimitriou H; Kambourakis A; Kalmanti M
Pediatr Hematol Oncol; 1999; 16(2):101-8. PubMed ID: 10100270
[TBL] [Abstract][Full Text] [Related]
9. Comparison of granisetron, ondansetron and tropisetron for control of vomiting and nausea induced by cisplatin.
Oge A; Alkiş N; Oge O; Kartum A
J Chemother; 2000 Feb; 12(1):105-8. PubMed ID: 10768522
[TBL] [Abstract][Full Text] [Related]
10. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
[TBL] [Abstract][Full Text] [Related]
11. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
[TBL] [Abstract][Full Text] [Related]
12. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
Gregory RE; Ettinger DS
Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
[TBL] [Abstract][Full Text] [Related]
13. Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting.
Plosker GL; Benfield P
Pharmacoeconomics; 1996 Apr; 9(4):357-74. PubMed ID: 10160110
[TBL] [Abstract][Full Text] [Related]
14. Improved anti-emetic efficacy of 5-HT3 receptor antagonists in cancer patients with genetic polymorphisms of ABCB1 (MDR1) drug transporter.
Zoto T; Kilickap S; Yasar U; Celik I; Bozkurt A; Babaoglu MO
Basic Clin Pharmacol Toxicol; 2015 Apr; 116(4):354-60. PubMed ID: 25286968
[TBL] [Abstract][Full Text] [Related]
15. Association of ABCB1 polymorphisms with the efficacy of ondansetron in chemotherapy-induced nausea and vomiting.
He H; Yin JY; Xu YJ; Li X; Zhang Y; Liu ZG; Zhou F; Zhai M; Li Y; Li XP; Wang Y; Zhou HH; Liu ZQ
Clin Ther; 2014 Aug; 36(8):1242-1252.e2. PubMed ID: 25012726
[TBL] [Abstract][Full Text] [Related]
16. Antiemetic therapy for high-dose chemotherapy with transplantation: report of a retrospective analysis of a 5-HT(3) regimen and literature review.
Perez EA; Tiemeier T; Solberg LA
Support Care Cancer; 1999 Nov; 7(6):413-24. PubMed ID: 10541984
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
[TBL] [Abstract][Full Text] [Related]
18. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
19. Granisetron in the control of radiotherapy-induced nausea and vomiting: a comparison with other antiemetic therapies.
Feyer P; Seegenschmiedt MH; Steingraeber M
Support Care Cancer; 2005 Sep; 13(9):671-8. PubMed ID: 16044252
[TBL] [Abstract][Full Text] [Related]
20. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis.
Jordan K; Hinke A; Grothey A; Voigt W; Arnold D; Wolf HH; Schmoll HJ
Support Care Cancer; 2007 Sep; 15(9):1023-33. PubMed ID: 17205281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
